Author

J. Zhuo

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:virus· 2 Assay:bulk RNA-seq· 1 Organism:human· 1

Frequent Co-Authors

A. Leung· 3 shared A. Roy· 2 shared D. K. Johnson· 2 shared D. V. Ferraris· 2 shared S. Wazir· 2 shared Y. M. Alhammad· 2 shared A. Fehr· 1 shared A. Foye· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiochemistry

A. Leung

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening

A. Roy, Y. M. Alhammad, P. McDonald, D. K. Johnson, J. Zhuo, S. Wazir, D. V. Ferraris, L. Lehtiö, A. Leung, A. R. Fehr

This study identifies 5 compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding through high-throughput screening, with IC50 values under 100 µM.

bioRxiv · Mar 1, 2022Biochemistry

Design, Synthesis and Evaluation of Inhibitors of the SARS-CoV-2 nsp3 Macrodomain

L. M. Sherrill, E. E. Joya, A. Walker, A. Roy, Y. M. Alhammad, M. Atobatele, S. Wazir, G. Abbas, P. Keane, J. Zhuo, A. Leung, D. K. Johnson, L. Lehtio, A. Fehr, D. V. Ferraris

This study designs and synthesizes inhibitors targeting the SARS-CoV-2 nsp3 macrodomain, identifying compound 15c as a low-micromolar inhibitor with structural and thermal evidence of binding.

bioRxiv · Feb 27, 2022 · PreprintBiochemistry

High-throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain

M. A. Dasovich, J. Zhuo, A. G. Thomas, J. A. Goodman, R. L. McPherson, A. K. Jayabalan, V. F. Busa, S.-J. Cheng, B. Murphy, K. R. Redinger, T. Tsukamoto, B. S. Slusher, J. Bosch, J. Wei, A. Leung

The paper develops a high-throughput assay for screening inhibitors of the SARS-CoV-2 Mac1 macrodomain and identifies dasatinib and dihydralazine as inhibitors with selectivity over human MacroD2.

bioRxiv · Oct 7, 2021Biochemistry

CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer

N. Zhao, k. Trepka, Y.-h. Wang, S. Chopra, N. Hooshdaran, H. Kim, J. Yang, J. Zhuo, S. Lim, K. K. Leung, E. Egusa, L. K. Zhang, A. Foye, J. Chou, F. Y. Feng, , R. Aggarwal

This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.

bioRxiv · Jun 17, 2021 · PreprintCancer Biology